argenx SE reported $914.57M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
AstraZeneca USD 12.53B 4.16B Dec/2025
Galapagos EUR 120.26M 7.43M Dec/2025
Genmab DKK 798M 235M Dec/2025
GlaxoSmithKline GBP 7.18B 1.42B Dec/2025
GRIFOLS EUR 1.71B 193M Dec/2025
Hikma Pharmaceutical USD 1.34B 702M Dec/2025
Qiagen NV USD 418.54M 23.25M Dec/2025
UCB EUR 2.96B 196M Dec/2025